BiotechTube

Mesenchymal stem cell + Placebo

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ischemic Heart Disease

Conditions

Ischemic Heart Disease

Trial Timeline

Sep 1, 2025 → Mar 31, 2029

NCT ID
NCT07192211

About Mesenchymal stem cell + Placebo

Mesenchymal stem cell + Placebo is a phase 2 stage product being developed by Rohto Pharmaceutical for Ischemic Heart Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07192211. Target conditions include Ischemic Heart Disease.

What happened to similar drugs?

10 of 14 similar drugs in Ischemic Heart Disease were approved

Approved (10) Terminated (3) Active (4)
✅RegadenosonAstellas PharmaApproved
✅StatinShionogiApproved
✅RepathaAmgenApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅celecoxib + ibuprofen + placeboPfizerApproved
✅Eplerenone + Placebo or sugar pillPfizerApproved
✅Enoxaparin sodiumSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07192211Phase 2Recruiting
NCT04888949Phase 2Completed

Competing Products

20 competing products in Ischemic Heart Disease

See all competitors
ProductCompanyStageHype Score
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
DS-1040b + AspirinDaiichi SankyoPhase 1
29
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
RegadenosonAstellas PharmaPhase 1
29
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
RegadenosonAstellas PharmaApproved
43
ASP2246Astellas PharmaPhase 1/2
39
Gadolinium + AdenosineAstellas PharmaPhase 2/3
38
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
fospropofol + propofolEisaiPhase 2
35
PDE5 InhibitorsEli LillyPre-clinical
26
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35
Elezanumab + PlaceboAbbViePhase 2
35
Balovaptan + PlaceboRochePhase 2
27
RepathaAmgenApproved
35
GS-6615 + PlaceboGilead SciencesPhase 1
29